Recurrence of neuroleptic malignant syndrome with olanzapine treatment.
Gheorghiu
S
S
Knobler
H Y
HY
Drumer
D
D
D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D002749:Chlorprothixene / Q000009:adverse effects; D003006:Clopenthixol / Q000009:adverse effects; D005260:Female; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy; D012008:Recurrence
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003006:Clopenthixol; D002749:Chlorprothixene; D000077152:Olanzapine